Advantage of using a recombinant activated factor VII in traumatic haemorrhagic shock: The Bordeaux experience

INTRODUCTION: Several series of patient studies have been published on the use of rFVIIa in traumatic haemorrhagic shock, although to date no international recommendations have been produced. France does not currently recognise traumatic haemorrhagic shock as an appropriate indication for the use of...

Descripción completa

Detalles Bibliográficos
Autores principales: Morel, Nicolas, Chabarttier, Cyrille, Merson, Laurent, Lelias, Agathe, Bernard, Jean-Christophe, Delaunay, François, Dabadie, Philippe, Janvier, Gérard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2012
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391838/
https://www.ncbi.nlm.nih.gov/pubmed/22787344
http://dx.doi.org/10.4103/0974-2700.96483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3391838/
https://www.ncbi.nlm.nih.gov/pubmed/22787344
http://dx.doi.org/10.4103/0974-2700.96483

Ejemplares similares